Stockscreener 앱 받기
0.5119
6.04%
-0.0329
시간 외 거래:
.52
0.0081
+1.58%
전일 마감가:
$0.5448
열려 있는:
$0.536
하루 거래량:
746.26K
Relative Volume:
0.07
시가총액:
$25.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-11.02%
1개월 성능:
+44.73%
6개월 성능:
-33.52%
1년 성능:
+0.00%
1일 변동 폭
$0.5084
$0.5499
1주일 범위
$0.5084
$0.5871
52주 변동 폭
$0.215
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
명칭
Aspire Biopharma Holdings Inc
전화
561-704-8527
주소
194 CANDELARO DRIVE, #233, HUMACAO
ASBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.5119 | 26.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Aspire Biopharma Reports Final Results in Sublingual Aspirin Trial for Heart Attack Treatment; Shares Fall Pre Bell - MarketScreener
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - New Castle News
2-Minute Response Time: Aspire's New Sublingual Aspirin Could Revolutionize Heart Attack Treatment - Stock Titan
How to track smart money flows in Banc of California Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Weekly Investment Recap & Fast Moving Market Watchlists - Newser
How to track smart money flows in aTyr Pharma Inc.2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
ExlService Holdings Inc. stock chart pattern explainedTrade Exit Summary & Free Safe Entry Trade Signal Reports - Newser
Combining price and volume data for Shell plc Depositary ReceiptEarnings Risk Summary & Technical Buy Zone Confirmation - Newser
Aspire Biopharma Secures $9.7M Through Securities Agreement - MSN
How to track smart money flows in TTEC Holdings Inc.2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Historical volatility pattern of Zoomcar Holdings Inc. visualizedJuly 2025 Trends & Precise Swing Trade Entry Alerts - Newser
What earnings revisions data tells us about Newton Golf Company Inc.July 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Risk vs reward if holding onto Edesa Biotech Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
What MACD and RSI say about CHSNWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Aspire Biopharma enters $9.7 million note purchase agreement with investors By Investing.com - Investing.com Nigeria
Aspire Biopharma's Debt Refinancing: A Strategic Play for Biotech Capital Structure Optimization and Operational Flexibility - AInvest
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Promising Penny Stocks To Consider – August 18th - Defense World
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On?Aspire Biopharma Hldgs (NASDAQ:ASBP) - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
ASBP.O (Aspire Biopharma) Surges Over 80%: What's Driving the Intraday Spike? - AInvest
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Miami Herald
Aspire Biopharma to Present at Sidoti Virtual Investor Conference - AInvest
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
New Pre-Workout BUZZ BOMB Hits Market With Instant-Acting Sublingual Technology - Stock Titan
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Lubbock Avalanche-Journal
Riding the Waves: A Guide to Investing in ASBP Stock - investchronicle.com
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
Aspire Biopharma Holdings Inc (ASBP) 재무 분석
Aspire Biopharma Holdings Inc (ASBP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):